What is the core difference between retatrutide and semaglutide?
The cleanest way to think about it is how many receptors each molecule activates. Semaglutide — the compound sold as Ozempic, Wegovy, and Rybelsus — is a single GLP-1 receptor agonist. Retatrutide is a triple agonist: it activates the GLP-1 receptor plus two more, GIP and glucagon.
That third target, the glucagon receptor, is the headline. Glucagon-receptor activity is linked to increased energy expenditure and reduced liver fat, which is the mechanistic rationale for the larger weight-loss figures retatrutide produced in early trials. Semaglutide leans entirely on GLP-1 — appetite suppression, slowed gastric emptying, and glucose-dependent insulin release.
The difference that matters most today, though, is regulatory: semaglutide is an approved medicine with years of real-world data, while retatrutide is still an investigational compound being studied in clinical trials.
Retatrutide vs Ozempic vs Wegovy vs Rybelsus: which name is which?
A lot of "retatrutide vs Ozempic" and "retatrutide vs Wegovy" searches are really the same question, because Ozempic, Wegovy, and Rybelsus are all brand names for one molecule: semaglutide. They differ by dose, route, and the indication the FDA approved them for, not by active ingredient.
Ozempic is once-weekly injectable semaglutide (0.5 mg, 1 mg, and 2 mg) approved for type 2 diabetes, with an added indication to reduce major adverse cardiovascular events in adults who have type 2 diabetes and established cardiovascular disease. Its diabetes evidence comes from the SUSTAIN program. Wegovy is the same molecule at a higher once-weekly dose (titrated to 2.4 mg) approved for chronic weight management in obesity or overweight with a weight-related condition; its evidence comes from the STEP program, and it also carries an FDA indication to reduce cardiovascular events in adults with established cardiovascular disease plus obesity or overweight. Rybelsus is oral semaglutide (7 mg and 14 mg once daily) approved for type 2 diabetes, studied in the PIONEER program.
Keeping the programs straight matters when you read trial numbers: STEP trials measure weight loss in obesity, while SUSTAIN and PIONEER trials measure glucose control (and cardiovascular safety) in diabetes. Retatrutide, by contrast, has a single investigational identity — LY3437943 — and no brand names at all, because no regulator has approved it. Its own phase 3 program is called TRIUMPH and is still ongoing as of 2026.
Which produced more weight loss in clinical trials?
In its phase 2 obesity trial, retatrutide at the 12 mg dose produced a mean weight reduction of roughly 24.2% at 48 weeks — among the largest figures reported for any weight-loss drug. The same trial reported a clear dose-response: about 17.1% at 4 mg and 22.8% at 8 mg at 48 weeks, against roughly 2.1% for placebo. Semaglutide, in the phase 3 STEP 1 trial, produced roughly 14.9% at the 2.4 mg dose over 68 weeks, versus about 2.4% for placebo — a treatment difference of about 12.4 percentage points.
Responder rates tell a similar story within each separate trial. In STEP 1, about 86.4% of semaglutide participants lost at least 5% of body weight, 69.1% lost at least 10%, and 50.5% lost at least 15% (versus 31.5%, 12.0%, and 4.9% on placebo). In the retatrutide phase 2 trial at 48 weeks, the 12 mg group reported 100% of participants losing at least 5%, 93% losing at least 10%, and 83% losing at least 15% — though this was a smaller, earlier-stage study.
It is important not to over-read this. These figures came from different trials, with different durations, dose schedules, and patient populations — they were never compared head-to-head, so the percentages are not directly subtractable. A larger phase 2 number does not guarantee superiority once retatrutide completes phase 3, where efficacy often moderates as the study population broadens and the trial runs longer. Semaglutide's number, by contrast, comes from a completed pivotal trial that supported an FDA approval. Treat the comparison as "what each drug did in its own study," not as a verdict.
How do they compare on cardiovascular outcomes?
This is the cleanest differentiator between the two, and it favors semaglutide today. Cardiovascular-outcomes trials are large, multi-year studies that count actual heart attacks, strokes, and cardiovascular deaths rather than weight or glucose — they are the gold standard for showing a drug changes hard clinical events, not just numbers on a chart.
Semaglutide has two such trials. In SELECT, a trial of adults with overweight or obesity and established cardiovascular disease but no diabetes, once-weekly semaglutide 2.4 mg cut the primary composite of cardiovascular death, nonfatal heart attack, or nonfatal stroke to 6.5% versus 8.0% on placebo — a hazard ratio of 0.80, roughly a 20% relative reduction. In SUSTAIN-6, in adults with type 2 diabetes at high cardiovascular risk, semaglutide reduced the same composite to 6.6% versus 8.9% (hazard ratio 0.74, about a 26% relative reduction).
Retatrutide has no comparable cardiovascular-outcomes data. As an investigational compound it has not completed — and at the time of writing has not reported — a dedicated cardiovascular-outcomes trial, so there is no evidence yet that it reduces heart attacks or strokes. Its trials did note dose-dependent increases in heart rate, a signal that any future cardiovascular-outcomes study will need to characterize. Until that evidence exists, semaglutide is the only one of the two with proven cardiovascular benefit.
How do the side effects compare?
Both drugs are dominated by gastrointestinal side effects — nausea, diarrhea, vomiting, and constipation — because both engage the GLP-1 system. In both, these effects are dose-dependent and tend to ease as the dose is escalated gradually.
Retatrutide trials additionally reported dose-dependent increases in heart rate that peaked around 24 weeks and then declined. Its long-term safety record is, by definition, thinner: semaglutide has been prescribed to millions and carries a large post-market safety database, while retatrutide's safety profile is still being characterized in ongoing trials. That asymmetry in evidence is itself a meaningful difference.
What about liver fat and metabolic-liver disease?
Liver fat is where retatrutide's glucagon arm shows up most strikingly in the data so far. A separate phase 2a trial studied retatrutide specifically in metabolic dysfunction-associated steatotic liver disease (MASLD, the condition formerly framed as non-alcoholic fatty liver disease). At 24 weeks the 12 mg dose produced a mean relative reduction in liver fat of roughly 82%, with about 86% of participants on that dose reaching normal liver fat (under 5%), versus essentially no change on placebo. Lower doses showed a clear dose-response.
Those are large reductions, but the context matters. This was an early-stage, 24-week study measuring liver fat on imaging — a biomarker — not a trial proving retatrutide reverses fibrosis, improves liver-related clinical outcomes, or earns a liver-disease indication. Retatrutide is not approved for MASLD or anything else.
Semaglutide also improves hepatic steatosis and is being studied in metabolic liver disease, but as with retatrutide, weight-management and diabetes are its approved uses, not liver disease per se. For anyone with fatty-liver concerns, the practical takeaway is the same regardless of compound: liver enzymes and metabolic markers should be monitored by a clinician, not self-managed off trial headlines.
Is retatrutide available, and is it legal?
Retatrutide is not approved by the FDA or any major regulator. The only lawful way to receive it is by enrolling in a clinical trial. Material sold online as "research" retatrutide is explicitly labeled not for human use and sits outside the regulated supply chain — its identity, purity, and sterility are unverified.
Semaglutide, by contrast, is available by prescription as Ozempic, Wegovy, or Rybelsus through licensed pharmacies. If weight management or glycemic control is the goal today, semaglutide is the option with an approval, a known supply chain, and an established safety record. Any GLP-1 decision should be made with a licensed clinician.
Tracking either compound on PeptidePanel
Whichever agent a clinician prescribes, the day-to-day work is the same: log doses, watch the biomarkers that matter (HbA1c, lipids, liver enzymes, weight trend), and catch side effects early. PeptidePanel is the neutral tracking layer for that — it records the protocol your clinician sets, charts your bloodwork against reference ranges, and reminds you when a dose or a lab is due.
PeptidePanel does not sell, source, supply, or prescribe any compound. It is a monitoring tool for protocols a qualified prescriber has put you on.